Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Prospective, Multicenter Study to Investigate the Specificity of in Vivo Antibody Binding to Red Blood Cells in Subjects With Chronic Immune Thrombocytopenic Purpura (ITP) Treated With IgPro10 (Privigen®) Who Have Shown Signs of Hemolysis

NCT01390649 is registered in ClinicalTrials.gov with CSL Behring as lead sponsor.

NCT NCT01390649
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01390649 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Prospective, Multicenter Study to Investigate the Specificity of in Vivo Antibody Binding to Red Blood Cells in Subjects With Chronic Immune Thrombocytopenic Purpura (ITP) Treated With IgPro10 (Privigen®) Who Have Shown Signs of Hemolysis
Lead sponsor
CSL Behring
Phase
Phase 4
Overall status
Completed
Start date
November 30, 2011
Completion date
September 30, 2014
Enrollment
57 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenic purpura